Hospital Universitario De La Princesa
Verified site
Madrid, Spain
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The study looks at a medication called almotriptan, which is used to treat migraine, a type of headache that can cause severe pain, nausea, and sensitivity to light. Two different tablet forms of the same medicine are being compared: one that dissolves quickly in the mouth (orodispersible tablet) and one that has a thin coating (film‑coated tablet). The purpose of the study is to see whether the body absorbs the two forms in the same way, meaning they are interchangeable for patients.
Healthy volunteers will fast (not eat) before taking a single dose of one tablet, and blood samples will be collected over several hours to measure how much of the drug reaches the bloodstream and how fast it appears. After a short break, the same participants will take the other tablet under the same conditions, and the same measurements will be repeated. This crossover design allows each person to serve as their own comparison, helping researchers determine if the two tablet types are essentially the same in how they work in the body.
The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.
6 criteria
13 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Madrid, Spain
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is the test medication used in this study. It is given as an oral tablet that dissolves quickly in the mouth (orodispersible). The purpose of using this form is to see how the drug is absorbed into the body compared with a standard tablet, helping researchers determine if the new formulation works the same way as the existing one.
is the reference medication in the trial. It is a film‑coated tablet that also contains almotriptan and is taken by mouth in the usual way. This product serves as the standard against which the test tablet is compared, allowing the study to check whether the two versions deliver the same amount of medicine to the bloodstream.
The test product is an oral orodispersible tablet that melts in the mouth and is taken once at a dose of 12.5 mg. Almotriptan is an approved medicine that is widely described in medical literature for treating migraine attacks. It works by stimulating specific serotonin receptors (5‑HT1B/1D), which narrows blood vessels in the brain and blocks pain signals. Pharmacologically it belongs to the triptan class of selective serotonin receptor agonists.
This comparator is an oral film‑coated tablet taken once with a dose of 12.5 mg after swallowing. Almogran is a commercial formulation of almotriptan that is also approved and well documented for the acute treatment of migraine. It acts by binding to serotonin 5‑HT1B/1D receptors, causing blood‑vessel constriction and reducing headache pain. It is classified as a triptan, a selective serotonin receptor agonist.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.